Structure Therapeutics’ (GPCR) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a $80.00 price objective on the stock.

Other analysts have also issued reports about the stock. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price target for the company. JMP Securities reiterated a “market outperform” rating and issued a $91.00 target price on shares of Structure Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $86.50.

Structure Therapeutics Trading Down 6.9 %

Shares of Structure Therapeutics stock opened at $27.90 on Thursday. Structure Therapeutics has a 1 year low of $26.23 and a 1 year high of $62.74. The company has a market cap of $1.60 billion, a P/E ratio of -37.70 and a beta of -3.41. The stock has a 50-day moving average price of $35.32 and a 200 day moving average price of $38.75.

Institutional Trading of Structure Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its holdings in shares of Structure Therapeutics by 230.0% during the 3rd quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock valued at $23,936,000 after purchasing an additional 380,115 shares in the last quarter. Exome Asset Management LLC acquired a new position in Structure Therapeutics during the third quarter worth $5,274,000. Franklin Resources Inc. raised its holdings in Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock valued at $30,991,000 after buying an additional 60,397 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 0.7% in the third quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Structure Therapeutics by 64.5% during the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after acquiring an additional 31,815 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.